Plasebo etkinin nörobiyolojisi

AKARSU, SÜLEYMAN; erdem, murat; GÜLSÜN, Murat

Plasebo etkinin nörobiyolojisi

Murat ERDEM, (Gülhane Askeri Tıp Fakültesi, Psikiyatri Anabilim Dalı, Ankara, Türkiye)

Süleyman AKARSU, (Gülhane Askeri Tıp Fakültesi, Psikiyatri Anabilim Dalı, Ankara, Türkiye)

Murat GÜLSÜN (Gülhane Askeri Tıp Fakültesi, Psikiyatri Anabilim Dalı, Ankara, Türkiye)

Psikiyatride Güncel Yaklaşımlar

9 1

Yıl: 2013 Cilt: 5 Sayı: 3 Sayfa Aralığı: 299 - 312 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Plasebo etkinin nörobiyolojisi

Öz:

Plasebo, tedavi edilen duruma yönelik özgületkisi olmayan madde ya da yö ntem olarak tanımlanmıştır. Plasebo, hoşnutluk durumuna yol açmakta, tıpkıbir ilacın etkisi gibi vücuttaki yolaklar aracılığıyla etkisini göstermektedir.Nörogörüntüleme yöntemlerinin gelişmesi ile plasebonun beyin aktivasyonu,nörotransmitterler ve hormonlar üzerinde çeşitli değişiklikler oluşturduğugözlenmiştir. Plasebo cevabının oluşmasında dopamin, serotonin, opioidsistemlerinin etkisi, plasebo etkisinin beklenti süreci ve ödül döngüsü ileilişkisi, farmakolojik ajanların etki ettiği beyindeki bazı özgül merkezlerinplasebo cevabı sırasındaki rolü çalışmalarda gösterilmiştir. Plasebo etkisi ilehipnozun etkisi arasında da benzerlikler vardır ve hem plasebo hem de hipnozyanıtında iyileşme beklentisi telkin fenomeni ile yakından ilişkilidir. Telkin vebeklenti modelleri ile ilişkili olarak hem hipnoz hem de plasebo uygulanımısonrası beyinde benzer değişiklikler oluşması ilgi çekmektedir. Beyindekinörokimyasal yolaklar izole olarak değil birçok ortak mekanizmalarla fonksiyonel etki oluşturmaktadır. Bu nedenle plasebo yanıtında tüm bu mekanizmalar birbirleriyle ilişkili olarak görev alabilirler. Her ne kadar birçok faktörünetkisi olduğu göz önünde bulundurulsa da; plasebonun etkisini anlamanın vebeyinde yaptığı değişiklikleri görüntüleyebilmenin, psikolo jik faktörlerinhastalıkların oluşumunda ve tedavisindeki rollerini aydınlatmada önemli yerivardır.

Anahtar Kelime:

Konular: Psikoloji

Neurobiology of placebo effect

Öz:

Placebo is defined as a substance or method that has no specific effect on thecondition being treated. Placebo leads to the state of contentment and showsits effects just like a drug by the pathways in the body. Various changesformed by plasebo on the brain activation, neurotransmitters and hormoneshave been observed with the development of neuroimaging methods. Theeffects of dopamine, serotonin, and opioid systems in the formation of theplacebo response; the relationship between placebo effect, reward cycle and expectation process and the role of the some specific regions in the brainwhere pharmacological agents acting on during the placebo response havebeen shown in several studies. There are similarities between hypnosis and theplacebo effects and expectation of improvement is closely related to the sug-gesting phenomenon in the hypnosis as well as placebo responses. The formation of similar changes in the brain after administration of placebo andhypnosis associated with the expectation models and suggestions attractsattention. Neurochemical pathways in the brain constitute functional impactwith many of the common mechanisms. Therefore, all of these mechanisms inthe placebo response can take part in relation to each other. Although it isknown that many factors may influence, understanding of the effects of placebo and viewing the changes in the brain formed by placebo have an important place for enlightening roles of psychological factors in the onset ofdiseases and treatment.

Anahtar Kelime:

Konular: Psikoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Brody H. The lie that heals: the ethics of giving placebos. Ann Intern Med 1982; 97:112-118.
2. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. J Neurosci 2005; 25:10390-10402.
3. Göka E. Plasebo kavramı ve plasebo etkisi. Turk Psikiyatri Derg 2002; 13:58-64.
4. Oken BS. Placebo effects: clinical aspects and neurobiology Brain 2008; 131:2812- 2823.
5. Stoessl AJ, de la Fuente-Fernandez R. Willing oneself better on placeboeffective in its own right. Lancet 2004; 364:227-228.
6. Colloca L, Benedetti F. Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 2005; 6:545-551.
7. Haour F. Mechanisms of the placebo effect and of conditioning. Neuroimmunomo- dulation 2005; 12:195-200.
8. Klosterhalfen S, Enck P. Psychobiology of the placebo response. Auton Neurosci 2006; 125:94-99.
9. Price DD, Craggs J, Verne GN, Perlstein WM, Robinson ME. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel synd- rome patients. Pain 2007; 127:63-72.
10. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinsons disease. Science 2001; 293:1164-1166.
11. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia imaging a shared neural network. Science 2002; 295:1737-1740.
12. Sokolik A, Casey KL, Davidson RJ, Kosslyn SM, Rose RM, Cohen JD. Placebo- induced changes in fMRI in the anticipation and experience of pain. Science 2004; 303:1162-1167.
13. Lieberman MD, Jarcho JM, Berman S, Naliboff BD, Suyenobu BY, Mandelkern M et al. The neural correlates of placebo effects: a disruption account. Neuroimage 2004; 22:447-455
14. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA et al. Placebo effects mediated endogenous opioid activity on mopioid receptors. J Neurosci 2005; 25:7754-7762.
15. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002; 159:122129.
16. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159:728-737.
17. Kaasinen V, Aalto S, Någren K, Rinne JO. Expectation of caffeine induces dopaminergic responses in humans. Eur J Neurosci 2004;19:2352-2356.
18. Ader R. Conditioned immunomodulation: research needs and directions. Brain Behav Immun 2002; 17:S51-S57.
19. Ader R, Cohen N. Behaviorally conditioned immunosuppression and murine syste- mic lupus erythematosus. Science 1982; 215:1534-1536.
20. Smith GR, McDaniel SM. Psychologically mediated effect on the delayed hypersensi- tivity reaction to tuberculin in humans. Psychosom Med 1983; 45:65-70.
21. Giang DW, Goodman AD, Schiffer RB, Mattson DH, Petrie M, Cohen N et al. Conditioning of cyclophosphamide-induced leukopenia in humans. J Neuropsychi- atry 1996; 8:194-201.
22. Ribeiro SCM, Tandon R, Grunhaus L, Greden JF. The DST as a predictor of out- come in depression: a meta-analysis. Am J Psychiatry 1993; 150: 618-1629.
23. Beecher HK. The powerful placebo. JAMA 1955; 159:1602-1606.
24. Melzack R. Evolution of the neuromatrix theory of pain. The Prithvi Raj Lecture: presented at the third World Congress of World Institute of Pain, Barcelona 2004. Pain Pract 2005; 5:85-94.
25. Knudsen L, Petersen GL, Nørskov KN, Vase L, Finnerup N, Jensen TS, et al. Review of neuroimaging studies related to pain modulation. Scand J Pain 2011; 2:108-120.
26. Fricchione G, Stefano GB. Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries. Med Sci Monit 2005; 11: MS54- MS65.
27. de la Fuente-Fernandéz R, Stoessl AJ. The placebo effect in Parkinsons disease. Trends Neurosci 2002; 25:299-303.
28. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ et al. Effects of expec- tation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychi- atry 2010; 67:857-865.
29. Pollo A, Torre E, Lopiano L, Rizzone M, Lanotte M, Cavanna A et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 2002; 13:1383-1386.
30. Benedetti F, Colloco L, Torre E, Lanotte M, Melcarne A, Pesare M et al. Placebo- responsive Parkinson patients show decreased activity in single neurons of subthala- mic nucleus. Nat Neurosci 2004; 7:587-588.
31. Irizarry KJL, Licinio J. An explanation for the placebo effect? Science 2005; 307:1411-1412.
32. Scott DJ, Stohler CS, Egnatuk CM, Want H, Koeppe RA, Zubieta JK. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 2007; 55:325-326.
33. Faria V. Mind really does matter: the neurobiology of placebo-induced anxiety relief in social anxiety disorder (Doctoral thesis). Uppsala, Uppsala University, 2012.
34. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: clues from Parkinsons disease. Biol Psychiatry 2004; 56:67-71.
35. Teixeira MZ, Guedes CHFF, Barreto PV, Martins MA. The placebo effect and ho- meopathy. Homeopathy 2010; 99:119-129.
36. Benedetti F, Lanotte M, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 2007; 147:260-271.
37. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K. Ingvar M. Placebo in emotional processing-induced expectations of anxiety relief activate a generalized mo- dulatory network. Neuron 2005; 46:957-969.
38. de la Fuente-Ferna´ndez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ et al. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 2002; 136:359-363.
39. Etkin A, Egner T, Kalisch R. Emotional processing in anterior cingulate and medial prefrontal cortex. Trends Cogn Sci 2011; 15:85-93.
40. Wager TD, Atlas LY, Leotti LA, Rilling JK. Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain expe- rience. J Neurosci 2011; 31:439-452.
41. Lyby PS, Aslaksen PM, Flaten MA. Is fear of pain related to placebo analgesia? J Psychosom Res 2010; 68:369-377.
42. Morton DL, Brown CA, Watson A, El-Deredy W, Jones A. Cognitive changes as a result of a single exposure to placebo. Neuropsychologia 2010; 48:1958-1964.
43. Furmark T, Appel L, Michelgård A, Wahlstedt K, Åhs F, Zancan S et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171 citalopram or placebo. Biol Psychiatry 2005; 58:132-142.
44. Peres JFP, Newberg AB, Mercante JP, Simão M, Albuquerque VE, Peres MJP et al. Cerebral blood flow changes during retrieval of traumatic memories before and after psychotherapy: a SPECT study. Psychol Med 2007; 37:1481-1491.
45. Fu CHY, Williams SCR, Cleare AJ, Brammer MJ, Walsh ND, Kim J et al. Attenua- tion of the neural response to sad faces in major depression by antidepressant treat- ment. Arch Gen Psychiatry 2004; 61:877-889.
46. Canli T, Congdon E, Gutknecht L, Constable RT, Lesch KP. Amygdala responsive- ness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm 2005; 112:1479-1485.
47. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D et al. Seroto- nin transporter genetic variation and the response of the human amygdala. Science 2002; 279:400-403.
48. Morton DL, Watson A, El-Deredy W, Jones AKP. Reproducibility of placebo analge- sia: effect of dispositional optimism. Pain 2009; 146:194-198.
49. Wager TD, Scott DJ, Zubieta JK. Placebo effects on human μ-opioid activity during pain. Proc Natl Acad Sci USA 2007; 104:11056-11061.
50. Zhang W, Luo J. The transferable placebo effect from pain to emotion: changes in behavior and EEG activity. Psychophysiology 2009; 46:626-634.
51. Zhang W, Qin S, Guo J, Luo J. A follow-up fMRI of a transferable placebo anxiolytic effect. Psychophysiology 2011; 48:1119-1128.
52. Bremner JD, Southwick SM, Charney DS. The neurobiology of posttraumatic stress disorder: an integration of animal and human research. In Posttraumatic Stress Disorder. A Comprehensive Text (Eds PA Saigh, JDBremner):103-143. Boston, Allyn and Bacon, 1999.
53. Grossman A: Opioids and stress in man. J Endocrinol 1988; 119:377-381.
54. Maier SF, Davies S, Grau JW, Jackson RL, Morrison DH, Moye T et al. Opiate antagonists and long-term analgesic reaction induced by inescapable shock in rats. J Comp Physiol Psychol 1980; 94:1172-1183.
55. Insel TR, Kinsley CH, Mann PE, Bridges RS. Prenatal stress has long-term effects on brain opiate receptors. Brain Res 1990; 511:93-97.
56. Sanchez MD, Milanes MV, Pazos A, Diaz A, Laorden ML, Autoradiographic eviden- ce of mu-opioid receptors down-regulation after prenatal stress in offspring rat brain. Brain Res Dev Brain Res 1996; 94:14-21.
57. Sanchez MD, Milanes MV, Pazos A, Diaz A, Laorden ML. Autoradiographic eviden- ce of delta-opioid receptor downregulation after prenatal stress in offspring rat brain. Pharmacology 2000; 60:13-18.
58. Myers RD. Neuroactive peptides: unique phases in research on mammalian brain over three decades. Peptides 1994; 15:367-381.
59. Friedman MJ. What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy? J Clin Psychiatry 2000; 61(Suppl 7):44-51.
60. Schmauss C, Yaksh TL. In vivo studies on spinal opiate receptor systems mediating amtinociciption. II. J Pharmacol Exp Ther 1984; 228:1-12.
61. Napier TC, Mitrovic I. Opioid modulation of ventral pallidal inputs. Ann N Y Acad Sci 1999; 877:176-201.
62. Schmauss C. Spinal kappa-opioid receptor-mediated antinociception is stimulus- specific. Eur J Pharmacol 1987; 137:197-205.
63. Steiner H, Gerfen CR. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 1998; 123:60-76.
64. Kalin NH, Sherman JE, Takahashi LK. Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Brain Res 1988; 457:130-135.
65. Quirarte GL, Galvez R, Roozendaal B, McGaugh JL. Norepinephrine release in the amygdala in response to footshock and opioid peptidergic drugs. Brain Res 1998; 808:134-140.
66. Howard JM, Olney JM, Frawley JP, Peterson RE, Smith LH, Davis JH et al. Studies of adrenal function in combat and wounded soldiers; a study in the Korean theatre. Ann Surg 1955; 141:314-320.
67. Sher L. The placebo effect on mood and behavior: possible role of opioid and dopa- mine modulation of the hypothalamic-pituitary-adrenal system. Forsch Komple- mentärmed Klass Naturheilkd 2003; 10:61-68.
68. Bendetti F, Amanzio M. The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Prog Neurobiol 1997; 51:109-125.
69. Zubieta JK, Bueller JA, Xu Y, Koeppe RA, Stohler CS. Neurochemical mediation of the placebo effect in humans; in: 59th Annual Convention of the Society of Biologi- cal Psychiatry New York. Biol Psychiatry 2004; 55:57S58S.
70. Katz RJ, Lott MH, Arbus P, Crocq L, Herlobsen P, Lingjaerde O et al. Pharmacothe- rapy of posttraumatic stress disorder with a novel psychotropic. Anxiety 1994-95; 1:169-174.
71. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283:1837-1844.
72. Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in posttrauma- tic stress disorder. Psychiatry Res 1988; 24:149-155.
73. Reist C, Kauffmann CD, Haier RJ, Sangdahl C, DeMet EM, Chicz-DeMet A. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 1989; 146:513-516.
74. Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane RM et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22:190-195.
75. Sher L. The role of endogenous opioids in the placebo effect in post-traumatic stress disorder. Forsch Komplementärmed Klass Naturheilkd 2004; 11:354-359.
76. Baker SL, Kirsch I. Hypnotic and placebo analgesia: order effects and the placebo label. Contemp Hypn 1993; 10:117-126.
77. Glass LB, and Barber TX. A note on hypnotic behavior the definition of the situation and the placebo effect. J Nerv Ment Dis 1961; 132:539-541.
78. Kirsch I, Hypnosis and placebos: response expectancy as a mediator of suggestion effects. Anales de Psicología 1999; 15:99-110.
79. Maquet P, Faymonville ME, Degueldre C, Delfiore G, Franck G, Luxen A et al. Functional neuroanatomy of hypnotic state. Biol Psychiatry 1999; 45:327-333.
80. Derbyshire SW, Whalley MG, Stenger VA, Oakley DA. Cerebral activation during hypnotically induced and imagined pain. Neuroimage 2004; 23:392-401.
81. Derbyshire SW, Whalley MG, Oakley DA. Fibromyalgia pain and its modulation by hypnotic and non-hypnotic suggestion: an fMRI analysis. Eur J Pain 2009; 13:542- 550.
82. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 1997; 277:968-971.
83. Wik G, Fischer H, Bragée B, Finer B, Fredrikson M. Functional anatomy of hypnotic analgesia: a PET study of patients with fibromyalgia. Eur J Pain 1999; 3:7-12.

APA	erdem m, AKARSU S, GÜLSÜN M (2013). Plasebo etkinin nörobiyolojisi. , 299 - 312.
Chicago	erdem murat,AKARSU SÜLEYMAN,GÜLSÜN Murat Plasebo etkinin nörobiyolojisi. (2013): 299 - 312.
MLA	erdem murat,AKARSU SÜLEYMAN,GÜLSÜN Murat Plasebo etkinin nörobiyolojisi. , 2013, ss.299 - 312.
AMA	erdem m,AKARSU S,GÜLSÜN M Plasebo etkinin nörobiyolojisi. . 2013; 299 - 312.
Vancouver	erdem m,AKARSU S,GÜLSÜN M Plasebo etkinin nörobiyolojisi. . 2013; 299 - 312.
IEEE	erdem m,AKARSU S,GÜLSÜN M "Plasebo etkinin nörobiyolojisi." , ss.299 - 312, 2013.
ISNAD	erdem, murat vd. "Plasebo etkinin nörobiyolojisi". (2013), 299-312.

APA	erdem m, AKARSU S, GÜLSÜN M (2013). Plasebo etkinin nörobiyolojisi. Psikiyatride Güncel Yaklaşımlar, 5(3), 299 - 312.
Chicago	erdem murat,AKARSU SÜLEYMAN,GÜLSÜN Murat Plasebo etkinin nörobiyolojisi. Psikiyatride Güncel Yaklaşımlar 5, no.3 (2013): 299 - 312.
MLA	erdem murat,AKARSU SÜLEYMAN,GÜLSÜN Murat Plasebo etkinin nörobiyolojisi. Psikiyatride Güncel Yaklaşımlar, vol.5, no.3, 2013, ss.299 - 312.
AMA	erdem m,AKARSU S,GÜLSÜN M Plasebo etkinin nörobiyolojisi. Psikiyatride Güncel Yaklaşımlar. 2013; 5(3): 299 - 312.
Vancouver	erdem m,AKARSU S,GÜLSÜN M Plasebo etkinin nörobiyolojisi. Psikiyatride Güncel Yaklaşımlar. 2013; 5(3): 299 - 312.
IEEE	erdem m,AKARSU S,GÜLSÜN M "Plasebo etkinin nörobiyolojisi." Psikiyatride Güncel Yaklaşımlar, 5, ss.299 - 312, 2013.
ISNAD	erdem, murat vd. "Plasebo etkinin nörobiyolojisi". Psikiyatride Güncel Yaklaşımlar 5/3 (2013), 299-312.